{
    "clinical_study": {
        "@rank": "16600", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "saline every 12 hours for 28 days"
            }, 
            {
                "arm_group_label": "Melatonin", 
                "arm_group_type": "Experimental", 
                "description": "Oral 30mg/12hours melatonin 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "OBJECTIVES. To establish the therapeutic efficiency of melatonin in adult patients with\n      severe sepsis and septic shock.\n\n      Specifically:\n\n        1. To evaluate the survival to 28 days of mechanical assisted ventilation, days with\n           vasoactive drugs, need of hemodialysis-hemofiltration, superinfection and evolution\n           towards the failure of other organs.\n\n        2. To evaluate, waiting for reduction under the influence of the treatment with melatonin,\n           :\n\n             1. clinical - analytical parameters of sepsis;\n\n             2. levels of cytokines;\n\n             3. oxidative and nitrosative stress;\n\n             4. acute-phase proteins (APP), specially of the ITIH4;\n\n             5. immune response;\n\n             6. endocrine response.\n\n      METHODOLOGY. Patients will be randomized in two groups, n = 55 in each group: 1) treatment\n      with melatonin 30mg/12 hours 28 days; 2) placebo.\n\n      Determinations: a) clinical - analytical parameters relative to the sepsis; b) melatonin\n      plasmatic levels; c) quantification of malonyldialdehyde and 4-hydroxynonenal, protein\n      carbonyl content, nitrites, erythrocyte membrane fluidity, and superoxide dismutase,\n      catalase,  glutathione reductase and glutathione peroxidase activity; d)\n      Interleukins-1,2,4,5, 6, 7,8,10,12,13, IFN-\u03b3; TNF-\u03b1 and GM-CSF; e) acute-phase proteins:\n      PCR, haptoglobin, Apo A-I, \u03b11-GPA and ITIH4; f) lymphocytes T, B, NK, T CD4, and T CD8, and\n      immunoglobulins; g) cortisol, aldosterone, ACTH, ADH, insulin, glucagon and\n      25-hydroxyvitamin D3. Data will be analyzed following a prospectively define plan and by\n      intention-to-treat (ITT) analysis."
        }, 
        "brief_title": "Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Severe Sepsis", 
            "Septic Shock"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Sepsis", 
                "Toxemia", 
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by\n      the Health Science Aragon Institute and its principal investigator is F. Agust\u00edn Garc\u00eda Gil\n      (Surgical Service). It will start in April-May 2013 and will finish 12 months later\n      approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients (males and females) over 18 years who meet the diagnostic criteria for\n             severe sepsis or septic shock secondary to community-acquired pneumonia or hospital\n             and or intra-abdominal infection\n\n        Exclusion Criteria:\n\n          -  Patient with more than 24 hours from the first documentation of organ dysfunction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858909", 
            "org_study_id": "TRA-172"
        }, 
        "intervention": {
            "arm_group_label": "Melatonin", 
            "description": "Administration via oral or via a nasogastric tube followed by 20mL saline", 
            "intervention_name": "Melatonin", 
            "intervention_type": "Drug", 
            "other_name": "Liquid 1 mg/mL Melatonin"
        }, 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Sepsis", 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zaragoza", 
                    "country": "Spain", 
                    "zip": "50009"
                }, 
                "name": "Hospital Cl\u00ednico Universitario Lozano Blesa"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III, Prospective, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock", 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednico Universitario Lozano Blesa", 
            "last_name": "Francisco A Garc\u00eda-Gil, Physician", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Mortality at 28 days of study entry.", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Days of mechanical ventilation. Days with vasoactive drugs. Days with hemodialysis or hemofiltration. Superinfection of organs other than the initial cause of the sepsis. Progression to other organs fail after starting the treatment.", 
                "measure": "Clinical evolution parameters", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "clinical - analytical parameters relative to the sepsis", 
                "measure": "Clinical evolution", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Melatonin plasmatic levels Quantification of malonyldialdehyde and 4-hydroxynonenal Protein carbonyl content Nitrites Erythrocyte membrane fluidity Superoxide dismutase, catalase,  glutathione reductase and glutathione peroxidase activity", 
                "measure": "Oxidative-nitrosative parameters", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Interleukins-1,2,4,5, 6, 7,8,10,12,13, IFN-\u03b3; TNF-\u03b1 and GM-CSF", 
                "measure": "Inflammatory parameters", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "PCR, haptoglobin, Apo A-I, \u03b11-GPA and ITIH4", 
                "measure": "Acute phase proteins", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Lymphocytes T, B, NK, T CD4, and T CD8, and immunoglobulins", 
                "measure": "Immune parameters", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Cortisol, aldosterone, ACTH, ADH, insulin, glucagon and 25-hydroxyvitamin D3", 
                "measure": "Endocrine parameters", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Aragon Institute of Health Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministerio de Sanidad, Servicios Sociales e Igualdad", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Aragon Institute of Health Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}